Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Volunteers
Health Professionals
What is the purpose of this trial?
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Abhijit Patel, MD, PhD
- Adam Boruchov, MD
- Agatha Hecht
- Alessia Donadio, MD
- Alison Johnson
- Allison Campbell, MD, PhD
- Anca Bulgaru, MD
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Bruce A. McGibbon, MD
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- Catherine Wei, MD
- Christin A. Knowlton, MD, MA
- Clarice Grens
- D. Barry Boyd, MD, MS
- Daniel Hicks, MD
- Daniel P. Petrylak, MD
- Elan Gorshein, DO, JD, MPH
- Emily Duffield, APRN
- Emily Kopas, APRN, OCN
- Francesca Montanari, MD
- Gloria Huang, MD, FACOG
- Harold Tara Jr, MD
- Henry S. Park, MD, MPH
- Jade Vanacore
- James Laird, MD
- James Vredenburgh, MD
- James E. Hansen, MD, MS
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Joseph Kim, MD
- Jung Yun Julie Kang, MD, PhD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kayla Martello
- Kelsey Martin, MD
- Kenneth B. Roberts, MD
- Kert Sabbath, MD, FACP
- Kevin Du, MD, PhD, MSCI
- Kimberly L. Johung, MD, PhD
- Kristen Hoxie
- Larisa Fleysher
- Lynn Mastrianni
- M. Sung Lee, MD
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Matthew Austin, MD
- Meena S. Moran, MD
- Melissa Rasar Young, MD, PhD
- Michael Burke
- Michael Cohenuram, MD
- Michael Grant, MD
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Nadine Housri, MD
- Neal Fischbach, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Rebecca Vanasse-Passas, MD
- Renee Moye
- Robert Legare, MD
- Robert Matera, MD
- Sanjay Aneja, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Goldberg, MD, MPH
- Sarah Thomen, APRN
- Shari Damast, MD
- Sharynn Hall, MD, PhD
- Stacey LaRosa
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Susan A. Higgins, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Thomas Hayman, MD, PhD
- Timothy Robinson, MD, PhD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yi An, MD
- Zia Rahman, MD
- Last Updated10/10/2024
- Study HIC#2000032279